Li X, Feng X S, Zhang Y H, Cui H, Li N, Dai M
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China Department of Medical Records, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou 450003, China.
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Jul 10;42(7):1174-1178. doi: 10.3760/cma.j.cn112338-20210118-00041.
The cohort study of lung cancer in high-risk population in communities in China was a part of Lung Cancer Cohort Study initiated in 2017 and funded by Precision Medicine Research of National Key Research and Development Program. Around 50 000 participants from the communities were enrolled from 7 cities in 7 regions in China. Information about the risk factors for lung cancer were collected and the populations at high risk for lung cancer were identified. Then, low-dose CT (LDCT) screening of lung cancer was conducted in the populations at high risk, and further information about the diagnosis of lung cancer cases and death cases were collected. Therefore, a community population-based cohort was established for lung cancer risk factor exposure survey, high risk population evaluation, LDCT screening and lung cancer case and death follow up. Meanwhile, biological samples were collected from all the participants in the cohort to support the future precision medicine research of lung cancer.
中国社区高危人群肺癌队列研究是2017年启动的肺癌队列研究的一部分，由国家重点研发计划精准医学研究资助。来自中国7个地区7个城市的约5万名社区参与者被纳入研究。收集了肺癌危险因素的信息，并确定了肺癌高危人群。然后，对高危人群进行低剂量CT（LDCT）肺癌筛查，并收集肺癌病例和死亡病例的进一步诊断信息。因此，建立了一个基于社区人群的队列，用于肺癌危险因素暴露调查、高危人群评估、LDCT筛查以及肺癌病例和死亡随访。同时，从队列中的所有参与者收集生物样本，以支持未来肺癌的精准医学研究。
